Health ❯ Pharmaceuticals

Clinical Trials

Drug Development Drug Safety Weight Loss Drugs Regulatory Compliance Regulatory Affairs Osteogenesis Imperfecta Weight Loss Cancer Treatment Obesity Treatments Regulatory Approval

Nektar Securities Suit Urges Investors To Seek Lead‑Plaintiff Status Before May 5

The case alleges protocol violations in the REZOLVE‑AA study that undercut results.

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Protocol Claims

Insmed Halts Brensocatib in Hidradenitis Suppurativa After Phase 2b Trial Fails

Soleno Investors Urged To Seek Lead Role in Securities Case Before May 5 Deadline

Law Firms Urge Nektar Investors to Join Securities Suit Before May 5

Investor Lawsuits Target Gossamer Bio Over Failed PROSERA Trial

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

Law Firm Seeks Nektar Investors to Lead Securities Suit Over REZOLVE‑AA Trial Claims

Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety Disclosures

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

Vistagen Investors Face March 16 Lead‑Plaintiff Deadline as Law Firms Seek Clients

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

Asundexian Cuts Recurrent Stroke 26% Without More Major Bleeding in Phase III

India Notifies Risk-Based Overhaul of Drug R&D Rules

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla